8-K: DURECT Corp Announces Positive Phase 2b Results for Larsucosterol in NEJM Evidence, Plans Phase 3 Trial

DURECT Corporation's larsucosterol shows promise in treating alcohol-associated hepatitis, with Phase 2b results published in NEJM Evidence and a Phase 3 trial planned.

Summary

• DURECT Corporation announced the publication of a peer-reviewed article in NEJM Evidence regarding the AHFIRM trial data for larsucosterol.
• The AHFIRM trial was a Phase 2b study evaluating larsucosterol for the treatment of severe alcohol-associated hepatitis (AH).
• The trial enrolled 307 patients across three arms: placebo, larsucosterol (30 mg), and larsucosterol (90 mg).
• Topline results from AHFIRM were previously announced by DURECT.
• The company plans to initiate a Phase 3 trial in 2025, pending funding, focusing on U.S. patients with 90-day mortality as the primary endpoint.
• The FDA has granted larsucosterol Fast Track Designation and Breakthrough Therapy Designation for the treatment of AH.
• AH is an acute form of alcohol-associated liver disease with high mortality rates and limited treatment options.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the promising Phase 2b results and the planned Phase 3 trial. However, the lack of statistical significance in the primary endpoint and the funding contingency temper the enthusiasm.

Positives

• Larsucosterol showed clinically meaningful trends in reducing 90-day mortality in AH patients.
• Mortality reductions were more pronounced in U.S. patients.
• Larsucosterol appeared safe and well tolerated in the AHFIRM trial.
• The FDA has granted larsucosterol Fast Track Designation and Breakthrough Therapy Designation.
• A single Phase 3 trial could be sufficient for NDA approval if successful.

Negatives

• The numerical improvement in the primary endpoint of mortality or liver transplant at 90 days did not achieve statistical significance for either dose of larsucosterol.
• The Phase 3 trial is pending funding, which introduces uncertainty.

Risks

• Future clinical trials of larsucosterol may not confirm the results from the AHFIRM trial.
• The company may not raise sufficient capital to commence or complete the Phase 3 clinical trial.
• The FDA may require additional clinical trials before approving larsucosterol.
• Breakthrough Therapy designation does not guarantee expedited FDA approval.
• The company's cash resources may be insufficient, affecting its ability to operate as a going concern.

Future Outlook

DURECT plans to initiate a Phase 3 trial of larsucosterol in 2025, pending funding, with the goal of demonstrating its potential in treating alcohol-associated hepatitis and potentially securing FDA approval.

Management Comments

• Dr. Mitchell Shiffman stated that they are encouraged by the AHFIRM data and look forward to further assessing the benefits of larsucosterol in AH patients in a Phase 3 trial.
• Norman Sussman commented that the publication of the AHFIRM data in NEJM Evidence underscores the importance of the clinical findings.
• James E. Brown added that they look forward to further demonstrating larsucosterol's potential in their upcoming Phase 3 trial.

Industry Context

The announcement addresses a significant unmet need in the treatment of alcohol-associated hepatitis, a condition with high mortality rates and limited FDA-approved therapies. The potential success of larsucosterol could provide a new treatment option for this patient population.

Comparison to Industry Standards

• The document mentions that many drugs and investigational agents have been evaluated for AH over decades, but none have proven consistently effective or received regulatory approval.
• The document cites a retrospective analysis of 77 studies published between 1971 and 2016, which included data from 8,184 patients, showed the overall mortality from AH was 26% at 28 days, 29% at 90 days and 44% at 180 days.
• A subsequent global study published in December 2021, which included 85 tertiary centers in 11 countries across 3 continents, prospectively enrolled 2,581 AH patients with a median Model of End-Stage Liver Disease (MELD) score of 23.5, reported mortality at 28 and 90 days of approximately 20% and 31%, respectively.

Stakeholder Impact

• Positive impact on patients with alcohol-associated hepatitis by potentially providing a new treatment option.
• Potential positive impact on shareholders if the Phase 3 trial is successful and larsucosterol receives FDA approval.
• Potential positive impact on the medical community by providing a new tool to combat AH.

Next Steps

• Initiate Phase 3 clinical trial of larsucosterol in 2025, pending funding.
• Focus the Phase 3 trial on U.S. patients with 90-day mortality as the primary endpoint.
• Pursue FDA approval for larsucosterol as a treatment for alcohol-associated hepatitis.

Key Dates